Literature DB >> 21806772

Overcoming obstacles in risk factor management in type 2 diabetes mellitus.

Yehuda Handelsman1, Paul S Jellinger.   

Abstract

Type 2 diabetes mellitus (T2DM) is characterized by progressively worsening hyperglycemia that leads to microvascular and macrovascular complications. Optimal management of T2DM aims to simultaneously control hyperglycemia, hypertension, and dyslipidemia to reduce the overall risk. However, a large proportion of patients in clinical practice do not reach treatment targets. Some of the obstacles to achieving treatment targets include high medication costs, costs associated with health insurance, poor patient adherence to medication, patient fear of potential adverse effects, improper patient education, and failure by health care providers to appropriately initiate or intensify therapy (clinical inertia). Possible causes of clinical inertia include the influence exerted on physicians by reluctant patients and the influence of media-driven attention and the negative spin of clinical trial results on physicians' prescribing behavior and on patients' attitudes towards treatment. This negative publicity can be disproportionate to the overall body of scientific evidence and may, therefore, prove to be unfounded in the long-term. There is clear evidence of the benefits of the effective management of T2DM to achieve goals. Overcoming the obstacles to achieving treatment targets may include use of strategies such as early intensive treatment and combination therapy with drugs with complementary mechanisms of action.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21806772      PMCID: PMC8108978          DOI: 10.1111/j.1751-7176.2011.00490.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  71 in total

Review 1.  Clinical inertia.

Authors:  L S Phillips; W T Branch; C B Cook; J P Doyle; I M El-Kebbi; D L Gallina; C D Miller; D C Ziemer; C S Barnes
Journal:  Ann Intern Med       Date:  2001-11-06       Impact factor: 25.391

2.  Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management.

Authors:  Richard Grant; Alyce S Adams; Connie Mah Trinacty; Fang Zhang; Ken Kleinman; Stephen B Soumerai; James B Meigs; Dennis Ross-Degnan
Journal:  Diabetes Care       Date:  2007-01-26       Impact factor: 19.112

3.  Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?

Authors:  Baiju R Shah; Janet E Hux; Andreas Laupacis; Bernard Zinman; Carl van Walraven
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

4.  Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.

Authors:  D Hunninghake; W Insull; P Toth; D Davidson; J M Donovan; S K Burke
Journal:  Atherosclerosis       Date:  2001-10       Impact factor: 5.162

5.  Clinical inertia contributes to poor diabetes control in a primary care setting.

Authors:  David C Ziemer; Christopher D Miller; Mary K Rhee; Joyce P Doyle; Clyde Watkins; Curtiss B Cook; Daniel L Gallina; Imad M El-Kebbi; Catherine S Barnes; Virginia G Dunbar; William T Branch; Lawrence S Phillips
Journal:  Diabetes Educ       Date:  2005 Jul-Aug       Impact factor: 2.140

6.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

7.  Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.

Authors:  J M Jonasson; R Ljung; M Talbäck; B Haglund; S Gudbjörnsdòttir; G Steineck
Journal:  Diabetologia       Date:  2009-07-09       Impact factor: 10.122

8.  Nurse-mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease.

Authors:  D M Becker; J V Raqueño; R M Yook; B G Kral; R S Blumenthal; T F Moy; P J Bezirdjian; L C Becker
Journal:  Arch Intern Med       Date:  1998-07-27

Review 9.  Managing hypertension in general practice: can we do better?

Authors:  J Hosie; I Wiklund
Journal:  J Hum Hypertens       Date:  1995-07       Impact factor: 3.012

10.  Impact of direct-to-consumer advertising (DTCA) on patient health-related behaviors and issues.

Authors:  Hyla H Polen; Nile M Khanfar; Kevin A Clauson
Journal:  Health Mark Q       Date:  2009 Jan-Mar
View more
  4 in total

1.  Adherence to the American Diabetes Association standards of care among patients with type 2 diabetes in primary care in Saudi Arabia.

Authors:  Turki J Al Harbi; Ayla M Tourkmani; Hesham I Al-Khashan; Adel M Mishriky; Hala Al Qahtani; Ahmed Bakhiet
Journal:  Saudi Med J       Date:  2015-02       Impact factor: 1.484

2.  Clinical inertia in individualising care for diabetes: is there time to do more in type 2 diabetes?

Authors:  William David Strain; Matthias Blüher; Païvi Paldánius
Journal:  Diabetes Ther       Date:  2014-08-12       Impact factor: 2.945

Review 3.  Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.

Authors:  Yehuda Handelsman
Journal:  Adv Ther       Date:  2019-08-23       Impact factor: 3.845

Review 4.  Multi-Target Approaches in Metabolic Syndrome.

Authors:  Felix F Lillich; John D Imig; Ewgenij Proschak
Journal:  Front Pharmacol       Date:  2021-03-12       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.